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LEISHMANICIDAL ACTIVITY OF Echinaster (Othilia) echinophorus CRUDE EXTRACT
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SUMMARY
In this study, a methanolic extract from Echinaster (Othilia) echinophorus was evaluated for activity against Leishmania 
amazonensis. The extract showed activity against the promastigote and amastigote forms with IC50 values of 62.9 and 37.5 μg.mL-1 
respectively. This extract showed a moderate toxicity on macrophages from BALB/c mice. A dose of 100 mg/kg/day was effective 
when administered during 15 days by intraperitoneal route to BALB/c mice infected experimentally. 
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INTRODUCTION
Leishmaniasis comprises a group of infectious diseases caused by 
organisms of the genus Leishmania and is a significant cause of morbidity 
and mortality in several countries34. The World Health Organization 
(WHO) estimates approximately 12 million affected individuals with 
an estimated annual incidence of 1.5 to 2 million. Approximately a 350 
million people live at risk in 88 different countries10. 
Due to the lack of a reliable human vaccine, in addition to the 
daunting control of parasite vectors and reservoirs, treatment relies 
exclusively on chemotherapy, with organic pentavalent antimonials 
as the first-line drugs17. Nevertheless, their efficacy is impaired by the 
growing incidence of parasite resistance and their frequent and severe side 
effects19. Alternative treatments, based on amphotericin B, paramomycin, 
allopurinol, and more recently miltefosine, are also available17, although 
most of these treatments give rise to secondary effects7. Thus, there is a 
pressing need for new leishmanicidal drugs. 
The marine organisms are a rich source of varied natural products 
with unique properties. Marine natural products chemistry has undergone 
an explosive growth during the past three decades11. Echinaster genus 
includes marine invertebrates that are usually associated with hard 
substrates; they generally live in shallow water, beneath coral rubble 
and rock and have been found clinging to mangrove roots18. In the 
literature, no pharmacological reports of antileishmanial activity for 
Echinaster species were found, although antimalarial activity has been 
described25. In this work, the in vitro and in vivo antileishmanial activity 
of an alcoholic extract of Echinaster echinophorus against Leishmania 
amazonensis is evaluated.
MATERIAL AND METHODS
1. Methanolic extract from E. echinophorus: Nine specimens of 
marine invertebrate E. echinophorus Lamarck 1816 (Echinodermata 
fam.) were collected by snorkelling and scuba diving at Puerto 
Esperanza (22°50ºN; 83° 46ºW), on the North coast of Pinar del Rio, 
Cuba, in February 2006. The sample was classified by Aida Hernández 
Sarduy, PhD and Macario Ezquivel, both specialists of The Institute of 
Oceanology and it was deposited at the Voucher Collection of National 
Aquarium of Cuba [IdO 10.1.0009].
The crude extract was prepared by homogenizing of the organisms 
(144.5 g wet weigh) with methanol pa. (Riedel-deHaën No 32213) at 70% 
using a Waring-Blendor homogenizer. The suspension was macerated at 4 
°C during 72 hours with mechanical agitation, followed by centrifugation 
at 10, 000 x g. The supernatant was concentrated using a vacuum rotary 
evaporator, lyophilized and stored at -20 °C. The lyophilized extract of 
E. echinophorus (0.5 g equal to 0.35% of yield) was dissolved in distilled 
water and partitioned with trichloromethane pa. (Merck No 2445) to 
get two fractions of different polarity. The qualitative phytochemical 
analyses were run for both fractions to identify the various types of 
secondary metabolites present, including saponins, flavonoids, phenols 
and tannins, glycosides, alkaloids, triterpenoids and steroids, amino acid 
and quinones8,23. 
2. Spectroscopy (UV- visible): The UV-visible spectrum of the crude 
extract was obtained in a Shimadzu spectrophotometer UV-1201 (Japan). 
The determination of the sample was made with a dilution of 1 mg.mL-1 
against methanol and the maximum of the absorbance in the range of 
200 to 800 nm, in the quartz cell of 1 cm of light pass.
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For their pharmacological evaluation, the extract and fractions were 
diluted in dimethyl sulphoxide (DMSO, BDH, Poole, England), at a 
concentration of 20 mg.mL-1, and stored at 4 °C.
3. Reference drug: Amphotericin B (AmB; Quimefa, Havana City, 
Cuba) was used as the reference drug, at a concentration of 2 mg.mL-1 
(stock solution). Dilutions of the drug were prepared using distilled water.
4. Parasites: The MHOM/77BR/LTB0016 strain of L. amazonensis 
was kindly provided by the Department of Immunology, Oswaldo Cruz 
Foundation (FIOCRUZ) Brazil. Parasites were routinely isolated from 
mouse lesions and maintained as promastigotes at 26 ºC in Schneider’s 
medium (SIGMA, St. Louis, MO, USA) containing 10% heat-inactivated 
fetal bovine serum (HFBS) (SIGMA, St. Louis, MO, USA), 100 μg.mL-1 
streptomycin, and 100 U.mL-1 penicillin. The parasites were used no later 
than ten passages in culture medium.
5. Laboratory animals: Female BALB/c mice, with a body weight 
of approximately 20-22 g, were obtained from the National Centre of 
Laboratory Animals Production (CENPALAB). The maintenance and 
care of mice was carried out following the guidelines from the Ethics 
Committee for the Human Use of Laboratory Animals. 
6. Biological evaluations 
6.1. Antipromastigote activity: Five concentrations of the crude 
extract of E. echinophorus were assayed. Exponentially growing cells 
(105 promastigotes.mL-1 in 198 μL of Schneider’s completed medium) 
were distributed in 96-well plates. Two microliters of extract dissolved 
in DMSO was added to well plates at a final concentration between 6.25 
and 200 μg.mL-1, and incubated at 26 °C. After three days of exposure, 
the parasites were incubated for three hours with p-nitrophenyl phosphate 
(20 mg. mL-1) dissolved in 1 mol.L-1 sodium acetate buffer (BDH, Poole, 
England), pH 5.5, with 1% Triton X-100 (BDH, Poole, England) at 37 
°C. The absorbance was determined in an EMS Reader MF Version 2.4-
0, at a wavelength of 405 nm3. The 50% of the inhibitory concentration 
(IC50) was obtained from dose-response curves fit to data by means of the 
lineal equation2. For testing AmB the same methodologies were followed 
with final concentration of AmB between 0.006 and 0.1 μg.mL-1. The 
control parasites were treated with 2 μL of DMSO (vehicle). This test 
was performed in triplicate. 
6.2. Antiamastigote activity: Resident macrophages were collected 
from peritoneal cavities of BALB/c mice in ice-cold RPMI 1640 medium 
(SIGMA, St. Louis, Mo, USA) supplemented with antibiotics, plated 
at 106/mL in 24-Well Lab-Tek (Costar, USA) and led to adhere for two 
hours at 37 ºC in 5% CO2. Non-adherent cells were removed by washing 
with PBS, and then, stationary-phase L. amazonensis promastigotes were 
added at a 4:1 parasite/macrophage ratio. The cultures were incubated 
for another four hours and the cell monolayers were washed three times 
with pre-warmed PBS to remove free parasites. Then, 980 μL of the 
RPMI complete medium and 20 μL of the extract, at final concentrations 
between 12.5 to 100 μg.mL-1, were added for a further 48 hours23. The 
cultures were then fixed with absolute methanol, stained with Giemsa, 
and examined under light microscopy. The number of intracellular 
amastigotes was determined by counting the amastigotes residents on 
100 macrophage per each sample, and the results were expressed as 
percent of reduction of the infection rate (% IR) in comparison to that 
of the controls [(IRTC = infection rate of the treated culture; IRUC = 
infection rate of the untreated culture)]. The infection rates were obtained 
by multiplying the percentage of infected macrophages by the number 
of amastigotes per infected macrophages9. The IC50 value was calculated 
by linear regression analysis. Each experiment was performed twice on 
different occasions. 
6.3. Cytotoxicity assay: The cytotoxicity of the extract was 
determined on peritoneal macrophages from BALB/c mice. Macrophages 
were collected and seeded at 105 cells. mL-1. After two hours of incubation 
at 37 ºC in 5% CO2, non-adherent cells were removed with PBS and 
2 μL of dilutions of the extracts was added to 198 μL of medium at 
10% of HFBS and antibiotics. The macrophages were treated with five 
concentrations of the extract, ranging from 12.5 to 200 μg.mL-1 for 48 
hours. Cultures treated with 2 μL of DMSO were included as controls. 
The cytotoxicity was determined using the colorimetric assay with 
3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) 
(SIGMA, St. Louis, MO, USA). MTT solutions were prepared at 5 
mg.mL-1 in PBS, filtered and sterilized at the time of use and 15 μL was 
added to each well. After incubation for an additional four hours the 
formazan crystals were dissolved by the addition of 100 μL of DMSO. 
The optical density was determined using an EMS Reader MF Version 
2.4-0, at a wavelength of 560 nm30. This test was performed in triplicate.
The IC50 was obtained from dose-response curves fitted to data by 
means of linear equation. The selectivity index (SI) ratio (=IC50 for 
macrophage/IC50 for amastigotes) was used to compare the toxicity of 
the extract for murine macrophage and the activity against intracellular 
amastigotes of Leishmania32.
7. In vivo studies: The activity of the crude extract of E. echinophorus 
was evaluated on mice experimentally infected with L. amazonensis. 
Groups of five BALB/c mice were randomly assigned to receive the 
extract dissolved in physiological saline solution. The treatment consisted 
of one daily intraperitoneal injection, at doses of 100 mg.kg-1 for two 
weeks. Mice were observed daily, the body weight of each mouse was 
measured each week from the beginning of the treatment up to six weeks 
post-infection. On day 0, mice were infected with 0.2 mL of parasite 
suspension containing 107 promastigotes of L. amazonensis, collected in 
the late logarithmic phase, by subcutaneous route in the right footpads. 
Disease progression was monitored by weekly assessment of the lesion 
diameters using an automatic calliper in vertical position. Average 
lesion size was calculated as the differences obtained between infected 
and uninfected footpads. At four and six weeks post-infection, three 
animals were sacrificed by cervical dislocation and the parasite burden 
was determined using the culture microtitre method3. A sample of the 
lesion was excised, weighed and homogenized in Schneider’s medium 
with 10% HFBS and antibiotics. Under sterile conditions 4-fold serial 
dilutions were prepared in wells of 96-well microtitre plates containing 
225 μL of culture medium and incubated at 26 oC. Three replicates were 
done of each piece. The presence or absence of mobile promastigotes 
in each well was verified after seven days of incubation. The parasite 
burden was calculated as follows: parasite burden = (geometric mean 
of reciprocal titres from each duplicated/weight of homogenized cross 
section) x 400. Data on lesion progression and parasite burden were 
analyzed for statistical significance by the analysis of variance test, 
following of a Post Hoc Test (LDS test or planned comparison) using 
the Statistical for Windows program, Version 4.5, StatSoft, Inc. 1993. 
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RESULTS
Ten qualitative chemical reactions were performed to identify the 
secondary metabolite components of the polar and non-polar fractions 
of the extract. We observed the presence of three groups of compounds 
in the aqueous fraction (amino acids, phenols and tannins and saponin) 
and only one type of component in the non polar phase (quinones). The 
results of spectral analysis of the methanolic extract of E. echinophorus 
showed three maxima corresponding with the following wavelengths: 
301nm (2,028); 362 nm (1,229); 466nm (0,533).
Table 1 shows the in vitro activity of the extract of E. echinophorus 
against L. amazonensis. The activity against intracellular amastigotes 
was two-fold higher than against the promastigote form with a SI of 9.
Treatment of mice with the extract did not result in animal death and 
the weight loss was less than 10% (Table 2). 
The effect of treatment on infected BALB/c mice with extract, vehicle 
or AmB by intraperitoneal route is presented in Fig. 1. A significant 
reduction (p < 0.05) in the size of the lesions from animals treated with 
the extract was observed at four weeks post-infection, compared to the 
other groups. After treatment, the lesions began to grow, although there 
was still a significant difference at week six of post-infection (p < 0.05). 
The mice treated with AmB had enlarging lesions, and the size of 
the lesions was statistically not different (p > 0.05) from the untreated 
group. Intraperitoneal treatment with vehicle induced no effect (p > 
0.05). 
The activity of the extract against Leishmania infections was verified 
by determination of the parasite burden in the lesion. We observed that 
the alcoholic extract produced a significant suppression (p < 0.05) of 
the number of parasites in the infected footpads, compared to the other 
test groups (Fig. 2). 
DISCUSSION
Active compounds from terrestrial and marine organisms have 
Table 1
In vitro activity of the extract of E. echinophorus and Amphotericin B against 
L. amazonensis
Tested drugs IC50 (μg.mL-1)a ± SDb SIc
promastigote amastigote macrophages
Extract of 
E. echinophorus
62.9 ± 1.3 37.5 ± 4.7 348.6 ± 2.4 9
Amphotericin B 0.03 ± 0.003 < 1 5.8 ± 0.5 193
a: IC50: Concentration of drug that caused 50% of mortality. To assay promastigote, 
a colorimetric method was used due to phosphatase activity. To assay amastigotes 
a direct counting of cultures stained by Giemsa was carried out. To assay macro-
phage a colorimetric method was performed with a tetrazolium salt (MTT). The 
control showed 5.2 ± 0.6 average of amastigote per macrophage and 96 ± 4% 
of macrophage infected; b: SD: standard deviation; c: SI: IC50 for macrophages/
IC50 for promastigotes.
Table 2
Mortality and corporal weight variation of BALB/c mice after 15 days of 
treatment with methanolic extract of E. echinophorus at 100 mg.kg-1 by 
intraperitoneal route
 
Groups Mortality 
(%)
Gain or loss of weight in mice (g)
Week 1 Week 2 Week 3 Week 4
E. echinophorus 0 1.0 6.1 5.4 13.9
Vehicle 0 4.0 4.0 7.5 15.0
Untreated 0 4.3 7.5 11.7 15.7
Fig. 1 - Effects of treatment with the methanolic extract of E. echinophorus (100 mg.kg-1) 
and Amphotericin B (1 mg.kg-1) administered daily for 15 days by intraperitoneal route, 
during the course of infection of BALB/c mice with L. amazonensis. Each point represents 
the mean ± the standard deviation of the mean difference in lesion size between infected and 
uninfected footpads of twelve mice. 
Fig. 2 - Parasite burden of mice infected with L. amazonensis and treated with the methanolic 
extract of E. echinophorus (100 mg.kg-1), Amphotericin B (1 mg.kg-1) and vehicle (0.1 mL) 
administered daily for 15 days by intraperitoneal routes. An untreated group was included 
as positive control. The determinations of parasite burden were carried out on the 15th and 
30th day of post-infection. The values represent the mean ± the standard deviation of the 
mean for three mice. 
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extensive use in the treatment of several diseases and serve as compounds 
of interest both in their natural form and as templates for synthetic 
modification. Over 20 new drugs derived from natural sources have been 
launched in the market during 2000-2005. These new drugs have been 
approved for the treatment of cancer, neurological diseases, infectious 
diseases, cardiovascular and metabolic diseases5. In this sense, previous 
compounds isolated from marine organism have been reported with 
antileishmanial activity; these include a glycoprotein isolated from 
Pachymatisma johnstoni24, a lectin from Cliona varians27 and three 
sulfated meroterpenoids from Callyspongia sp.16.
Previous studies have reported the isolation of “asterosaponins” 
from Echinaster braziliensis20; similarly, the phytochemical analysis 
of the extract of E. echinophorus revealed the presence of amino acids, 
phenols and saponins in the aqueous phase, and of quinones in the organic 
phase. Both saponins12,14,15,24 and quinones31 have shown activity against 
Leishmania parasites. 
The extract of E. echinophorus showed activity against both 
promastigotes and amastigotes forms of the parasite. In parallel evaluation 
of the cytotoxicity of the extract against host cells, the extract showed a 
selectivity index (SI) of nine; this is particularly relevant since it has been 
reported that products with an SI value greater than one are considered to 
be more selective in their activity against parasites, while those with an SI 
value lower than one are considered more selective in their activity against 
host cells6,32. The SI shown by the extract of E. echinophorus indicated that 
the action of the extract is specific for the Leishmania parasites and that it is 
not toxic for mouse peritoneal macrophages. The IC50 and SI values shown 
by the extract of E. equinophorus justify its evaluation against leishmaniasis 
in an animal model of infection, with the objective of validating the extract 
as a promissory source of antileishmanial products.
Even though experimental cutaneous leishmaniasis caused by L. 
amazonensis has been used in several studies evaluating new natural4,9,13,28 
and synthetic antileishmanial products4,26, treatment of animals infected 
with L. amazonensis with the extract of E. echinophorus reduced the 
size of the lesions and the parasite load in the infected footpads without 
causing death, loss of weight or any observable signs of toxicity. However, 
the cure was not complete; possibly because L. amazonensis-infected 
BALB/c mice are not adequate for testing the effectiveness of products 
against leishmaniasis, because a high multiplication rate of parasites 
at the site of the lesion occurs14. In addition, BALB/c mice are highly 
susceptible to Leishmania parasites, showing a progressive infection that 
may promote metastasis1, and are more susceptible to L. amazonensis 
than other inbred mice21. 
It is interesting to point out that in our study, AmB did not prevent 
the progression of the cutaneous disease in infected animals even 
though the susceptibility of the strain of L. amazonensis to AmB was 
confirmed (Table 2) and the dose of the drug administered by parenteral 
route was similar to that recommended in the literature. These results, 
i.e. the low effectivity of AmB in animals experimentally infected with 
L. amazonensis, are in agreement with those reported in the literature1. 
In conclusion, we believe that the extract of E. echinophorus 
represents a potential source on new antileishmanial natural products 
because of its activity against the parasite causing cutaneous leishmaniasis 
and its low toxicity. 
RESUMO
Atividade leishmanicida do extrato de Echinaster (Othilia) 
echinophorus
Neste estudo descreve-se o efeito de um extrato metanólico de 
Echinaster echinophorus spp. no parasita Leishmania amazonensis. Em 
testes com as formas promastigotas e amastigotas, o IC50 do extrato foi 
62,9 e 37,5 μg.mL-1, respectivamente. O extrato também tem toxicidade 
moderada em macrófagos de camundongos BALB/c. O tratamento 
de camundongos BALB/c infectados com L. amazonensis com doses 
diárias de 100 mg/kg/dia via intraperitoneal durante 15 dias mostrou-se 
relativamente efetivo no controle da infecção. Esta investigação confirma 
a importância de produtos naturais como fonte para a descoberta de 
fármacos com funções anti-Leishmania.
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